Education
About Us
Working with TipRanks
Follow Us
Marinus Pharmaceuticals Inc (MRNS)
:MRNS
MRNS Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Marinus News
MRNS FAQ
What was Marinus Pharmaceuticals Inc’s price range in the past 12 months?
Currently, no data Available
What is Marinus Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Marinus Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Marinus Pharmaceuticals Inc’s earnings last quarter?
Currently, no data Available
Is Marinus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Marinus Pharmaceuticals Inc’s price is currently Undervalued.
Does Marinus Pharmaceuticals Inc pay dividends?
Marinus Pharmaceuticals Inc does not currently pay dividends.
What is Marinus Pharmaceuticals Inc’s EPS estimate?
Marinus Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marinus Pharmaceuticals Inc have?
Currently, no data Available
What happened to Marinus Pharmaceuticals Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Marinus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MRNS
Company Description
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc. (MRNS) is a pharmaceutical company focused on developing innovative therapies to treat rare seizure disorders. The company's primary product, Ganaxolone, is a novel drug that acts as a GABA receptor modulator, designed to provide treatment options for patients with unmet medical needs, including those suffering from CDKL5 deficiency disorder and other seizure-related conditions.
Marinus (MRNS) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
ACADIA Pharmaceuticals
―
Catalyst Pharma
―
Sarepta Therapeutics
―
PTC Therapeutics
―
SAGE Therapeutics
―
Ownership Overview
―
Insiders
0.26%
Mutual Funds
― Other Institutional Investors
99.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---